Categories Uncategorized

Brain Cancer Affecting Young Military Veterans in the US

PTSD and traumatic brain injuries are the primary indications affecting veterans, with almost 500,000 troops living with these diseases. However, thousands more have also been diagnosed as having illnesses that may be connected to toxic waste and environmental hazards.

Hundreds of veterans are fighting glioblastoma, with some succumbing to the fatal disease. Glioblastoma is a common and aggressive type of cancer affecting the brain. It occurs in an individual’s spinal cord or brain. Research done on veterans and military personnel to determine why glioblastoma rates are higher in the active-duty population in comparison to the population in general haven’t produced any conclusive results.

After colon cancer and leukemia, glioblastoma ranks as the third most frequent cause of cancer-linked deaths in this particular population. Figures show that rates of glioblastoma in post-9/11 military veterans who were deployed to Afghanistan and Iraq, among other places, is more than 25% higher than that in the overall population. According to the National Institutes of Health, the occurrence of glioblastoma within the population is about 3.2 cases in every 100,000 individuals, with 64 being the average age of onset.

However, data from the Department of Veterans Affairs shows that the frequency of this brain cancer averages at 5.2 cases in every 100,000 people annually from 2015 to 2019, among post-9/11 veterans who have VA health care and were deployed. This is alarming as almost one-half of the population is made up of individuals aged 30 to 39. Data from the department also shows that the figures among Persian Gulf and Vietnam veterans are also elevated, at 6.2 cases for every 100,000 people annually from 2015 to 2019.

The department automatically grants benefits to service members diagnosed with brain cancer while on duty as well as veterans who were exposed to radiation while on active duty or those who develop the ailment within one year of being discharged. All other veterans have to file a compensation claim for disability, with stats showing that since 2002, more than 10,000 veterans suffering from brain cancer or the surviving family members of military veterans from as far back in the Persian Gulf, Vietnam and post-9/11 military missions have filed claims.

In an interview, the VA revealed that the rate at which claims are approved was about 31% for veterans of the Gulf-war period while that of post-9/11 military veterans was better, at 57%. Many hope that claiming benefits for brain cancer will get easier after an announcement made by the VA last year that it would review if various cancers needed to be fast-tracked for disability benefits. If this happens, more military veterans could stand a chance of benefiting from the brain cancer treatments commercialized by entities such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Lung Cancer Screening is Still Woefully Low in the US, Report Shows

A recent report published by the American Lung Association shows that only a tiny fraction…

2 hours ago

Soligenix Inc. (NASDAQ: SNGX) Strengthens Advisory Leadership in Cutaneous T-Cell Lymphoma

Soligenix revealed updates to its U.S. Medical Advisory Board for CTCL designed to support the…

24 hours ago

Sapu Nano Reveals the Initial In-Human Clinical Trial of Sapu-003, Intravenous Everolimus (Afinitor(R)) at Australian Translational Breast Cancer Symposium

The company revealed the trial at the Australia Translational Breast Cancer Research Symposium (“ATBCR”) Sapu-003…

1 day ago

How Rural Health Care is Being Impacted by the Federal Funding Landscape

Approximately 20% of people in the U.S. live in a rural area, and they face…

4 days ago

$37.5M Grant Announced to Boost Management of Infectious Diseases in the US

On October 15, NETEC (National Emerging Special Pathogens Training & Education Center) announced a grant…

5 days ago

What Patients Need to Know About the Remission Rate of Glioblastomas

Patients are overwhelmed when they are diagnosed with glioblastoma, the most deadly primary brain cancer.…

1 week ago